Premium
Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study
Author(s) -
Ahlehoff O.,
Hansen P.R.,
Gislason G.H.,
Frydland M.,
Bryld L.E.,
Elming H.,
Jemec G.B.E.
Publication year - 2016
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.13152
Subject(s) - medicine , ejection fraction , psoriasis , subclinical infection , psoriasis area and severity index , cardiology , diastole , prospective cohort study , body mass index , heart failure , blood pressure , dermatology
Abstract Background Psoriasis is a chronic inflammatory disease and is associated with cardiovascular events. Little is known about subclinical myocardial dysfunction and potential changes in myocardial function during anti‐inflammatory treatment in these patients. We prospectively studied left ventricular function in patients with severe psoriasis who initiated biologic therapy. Methods Between November 1 2013 and May 31 2014 the study subjects underwent physical, laboratory and comprehensive echocardiographic examination at baseline and after 3 months of treatment. Pearson correlation coefficients and Student's t ‐test were applied to assess changes in diastolic function (defined as the E/e’ ratio) and global longitudinal strain ( GLS ). Results Eighteen patients with severe psoriasis treated with biologic therapy with a mean follow‐up of 85.6 ± 18.2 days were included. The patients had a baseline psoriasis area and severity index ( PASI ) of 12.0 ± 4.1 and normal left ventricular ejection fraction [( LVEF ) 56.3 ± 3.8%], diastolic dysfunction (E/e′ 8.1 ± 2.1) and GLS (−16.8 ± 2.1%). At follow‐up, an improvement (baseline vs. follow‐up) of PASI (12.0 ± 4.1 vs. 2.7 ± 3.1, P < 0.001), E/e′ (8.1 ± 2.1 vs. 6.7 ± 1.9, P ≤ 0.001) and GLS (−16.8 ± 2.1 vs. −18.3 ± 2.3%, P < 0.001) were recorded. No changes were demonstrated in LVEF (56.3 ± 3.8 vs. 56.8 ± 3.3%, P = 0.31), body mass index (30.9 ± 5.7 vs. 31.0 ± 5.8 kg/m 2 , P = 0.90), mean arterial blood pressure (103.1 ± 8.5 vs. 103.7 ± 10.8 mmHg, P = 0.74). Likewise, no changes were seen in total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, estimated glomerular filtration rate and glycosylated haemoglobin. Conclusion In patients with severe psoriasis treatment with biologic therapy was associated with improved PASI and amelioration of myocardial dysfunction.